Screener
Monte Rosa Therapeutics, Inc. GLUE Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:09 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336711
| (in thousands, except share and per share amounts) | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total current liabilities | 59,658 | 64,212 |
| Deferred revenue, net of current | 105,623 | 111,332 |
| Defined benefit plan liability | 5,242 | 5,265 |
| Operating lease liability, net of current | 33,357 | 34,794 |
| Total liabilities | 203,880 | 215,603 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized | — | — |
Item 1. Financial Statements
FAQ
- What is Monte Rosa Therapeutics, Inc.'s operating lease liabilities?
- Monte Rosa Therapeutics, Inc. (GLUE) reported operating lease liabilities of $33.36M in Q2 2026.
- How has Monte Rosa Therapeutics, Inc.'s operating lease liabilities changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s operating lease liabilities decreased by 9.9% year-over-year, from $37.04M to $33.36M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about Monte Rosa Therapeutics, Inc.'s operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude